Summary After injection of "'In-labelled DTPA-D-Phel-octreotide, intraoperative tumour localisation was performed using a scintillation detector in 23 patients with neuroendocrine tumours. Count rates from suspect tumour lesions and adjacent normal tissue were expressed as a ratio before (Rin situ) and after (Rex vi,,) 
In autoradiographic studies and studies of tumour cell membranes, somatostatin receptors have been demonstrated on several kinds of neuroendocrine tumours (Reubi et al., 1987 . Five different somatostatin receptor subtypes have been identified so far and their sequences have been determined in man and in the rat. They all belong to the superfamily of receptors with seven transmembrane domains coupled to G-proteins. The widely used somatostatin analogue octreotide binds to the type 2 receptor with high affinity, but also to a lesser degree to the type 3 and 5 receptors (Bruns et al., 1994) . By using radiolabelled octreotide ("'In-labelled DTPA-D-Phe'-octreotide or 1231_ labelled Tyr3-octreotide) a sensitive scintigraphic technique for localisation of somatostatin receptor-positive tumours has been developed (Bakker et al., 1991; Lamberts et al., 1990) . The high sensitivity and specificity of the scintigraphic method in midgut carcinoid tumours (Ahlman et al., 1994) form the basis of the present study. We have evaluated the use of a handheld scintillation detector for intraoperative localisation of somatostatin receptor-positive tumours in addition to preoperative scintigraphy. The Ten patients had residual MTCs after previous total thyroidectomy and regional lymph node clearance (Table I) . They had been subjected to 1-4 neck dissections owing to recurrent tumour. They all had elevated calcitonin levels at pentagastrin provocation tests showing residual disease.
Another group comprised six patients with various neuroendocrine tumours (Table I) Scintillation detector and intraoperative measurements The scintillation detector system (TecProbe 2000, Stratec Elektronik, Birkenfeld, Germany) was equipped with a handheld 17 x 2 cm silver-anodised aluminium tube, containing a caesium iodide crystal collimated with a lead shield (aperture diameter 8 mm over a length of 10 mm). The probe was connected to a portable ratemeter. The energy window was 140-200 keV. A sterile dressing was drawn over the probe, which was held close to the tissue examined.
With the scintillation detector the mean count rates in situ over the suspect tumour lesion and the adjacent normal tissue were recorded. The ratio, Rin si,u, between the two measurements was calculated. Three to five recordings were performed with the detector held perpendicular to each tissue. Each recording lasted 3-10 s. To avoid contribution from "'In activity from tissues with high activity concentration, e.g. liver, spleen, and kidneys, the probe was directed away from these tissues, but extra shielding was not used mainly owing to restricted anatomical space. The count rates of excised tumour and normal tissue were also measured ex vivo and the ratio Rex vivo, was calculated. All neck explorations were performed by one surgeon and all abdominal explorations by another surgeon in order to minimise interindividual variability. Both surgeons were experienced endocrine surgeons working with minimal traumatic technique in all surgical fields.
Measurements of tissue samples
Before histopathological examination the surgical specimens together with blood samples drawn during surgery were weighed and the "'In activity concentration was measured in a calibrated gamma counter equipped with a sodium iodide well crystal (diameter 7.6 cm, length 7.6 cm, Harshaw, De Meern, Holland). The hole in the crystal had a diameter of 3 cm and a depth of 6 cm. A single-channel pulse-height analyser (Elscint, Haifa, Israel) was used. Corrections were made for background activity and radioactive decay. Tissue (Ti) to blood (B) "'In activity concentrations ratios, Ti/B were calculated. Tumour (T) to blood (B) "'In activity concentrations ratios (T/B) were calculated for histologyproven tumour lesions.
Statistical analyses of intraoperative measurements
The standard deviation of the difference between the mean number of counts from suspect tumour tissue (Ti) and normal tissue (N) was estimated:
where Ti' and N' are mean count rates from suspect tumour tissue and normal tissue, tTi and tN are integration times and nTl and nN number of measurements for suspect tumour tissue and normal tissue respectively. If the difference between the mean numbers of counts from suspect tumour tissue and normal tissue exceeded two standard deviations, the difference was regarded as statistically significant (P < 0.05). The T/B ratios for MC tumours varied between 27 and 650 and were only a little influenced by time; even 7 days after injection of the radiopharmaceutical the T/B ratios remained very high in this tumour type (Table I) .
The results of probe measurements and Ti/B calculations in an MC patient (no. 3) undergoing primary surgery 48 h after injection are shown in Figure 1 . In situ the scintillation detector correctly indicated tumour in regional lymph nodes and hepatic lesions, but gave a false-positive result of a parametrial cyst. The primary tumour gave a false-negative reading despite a positive scintigraphic finding. The discrimination was improved by using the scintillation detector ex vivo (Figure 1 ). The best discrimination was, however, obtained from Ti/B ratios. In this patient, normal tissues had ratios varying between 5 and 11 and tumour tissues had ratios between 51 and 220. The T/B ratios for MTC tumours seemed to be little influenced by time, but they were considerably lower (3-39) than those seen in MC tumours (Table I) .
The results of probe measurements and Ti/B calculations in an MTC patient (no. 11) undergoing repeat neck exploration 48 h after injection is shown in Figure 2 . In situ the probe correctly discriminated between tumour in lymph nodes vs normal lymph nodes and fat tissue. The ex vivo ratios were increased in comparison with in situ ratios. The Ti/B ratios for normal tissues varied between 3.8 and 5.7 in comparison with 31 and 32 for tumour tissue. ["'In] DTPA-D-Phel-octreotide in tumour detection gave correct information (Figure 3 scintigraphy using "'In-labelled DTPA-D-Phe'-octreotide and "23I-labelled Tyr3-octreotide 86% of patients with clinically proven MC had otherwise diagnosed tumour sites visualised. The corresponding figure for MTC patients was clearly lower, 65%. In a previous evaluation of the efficacy of scintigraphy in MC patients we found a higher sensitivity than conventional radiology (CT/US) and a high specificity (Ahlman et al., 1994) . In the present study T/B ratios varied considerably between the different scintigraphy-positive neuroendocrine tumour types; in MC tumours the ratio was 27-650, in a gastric carcinoid 71-210, in MTC 3-39 and in EPT 910 -1500. These high ratios would be expected to facilitate detection of tumours with intraoperative scintillation detection in comparison with, for example, radioimmunoguided surgery using radiolabelled monoclonal antibodies (Curtet et al., 1990; Sardi et al., 1989) . Earlier limited studies on probe-guided surgery using radiolabelled octreotide in patients with neuroendocrine tumours (Ahlman et al., 1994; Schirmer et al., 1993; Waddington et al., 1994) have been promising in individual patients. However, in this study in situ measurements with the present detection system (scintillation detector, ligand and isotope) gave lower ratios than expected from the high T/B ratios and thus added limited information to the preoperative scintigraphy and macroscopic findings during surgery. (24-168 h) . This indicates a similar decline in "'In activity of tumour and non-tumour tissues, including blood, after the initial 24 h (Krenning et al., 1992) .
The total volume of the tumour is important for the signal. This partly explains the marked difference in T/B ratios between MC tumours and MTC. MTC patients, undergoing neck re-exploration, often had lymph nodes with microscopic tumour burden and consequently less total "'In content than the large lymph node metastases of MC tumours. In studies using radiolabelled monoclonal antibodies on experimental tumours (Pedley et al., 1987; Williams et al., 1988) , a decreasing concentration has been shown with increasing tumour size, but this has not been corroborated in our studies on patients receiving "'In-labelled DTPA-D-Phe'-octreotide (Forssell-Aronsson et al., 1995) .
Considering the high T/B ratios for all tumours studied, in comparison with the moderate ratios from the probe measurements, future improvement of the technique must be evaluated: (1) 
